- Home
- ATOS vs QUIK Comparison
ATOS vs QUIK Comparison
Compare ATOS & QUIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- QUIK
- Stock Information
- Founded
- ATOS 2009
- QUIK 1988
- Country
- ATOS United States
- QUIK United States
- Employees
- ATOS N/A
- QUIK N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- QUIK Semiconductors
- Sector
- ATOS Health Care
- QUIK Technology
- Exchange
- ATOS Nasdaq
- QUIK Nasdaq
- Market Cap
- ATOS 107.2M
- QUIK 100.1M
- IPO Year
- ATOS 2012
- QUIK 1997
- Fundamental
- Price
- ATOS $0.82
- QUIK $6.17
- Analyst Decision
- ATOS Strong Buy
- QUIK Strong Buy
- Analyst Count
- ATOS 3
- QUIK 3
- Target Price
- ATOS $6.17
- QUIK $10.87
- AVG Volume (30 Days)
- ATOS 1.4M
- QUIK 182.6K
- Earning Date
- ATOS 08-15-2025
- QUIK 08-12-2025
- Dividend Yield
- ATOS N/A
- QUIK N/A
- EPS Growth
- ATOS N/A
- QUIK N/A
- EPS
- ATOS N/A
- QUIK N/A
- Revenue
- ATOS N/A
- QUIK $18,768,000.00
- Revenue This Year
- ATOS N/A
- QUIK $11.58
- Revenue Next Year
- ATOS N/A
- QUIK $40.23
- P/E Ratio
- ATOS N/A
- QUIK N/A
- Revenue Growth
- ATOS N/A
- QUIK N/A
- 52 Week Low
- ATOS $0.55
- QUIK $4.26
- 52 Week High
- ATOS $1.66
- QUIK $13.36
- Technical
- Relative Strength Index (RSI)
- ATOS 44.93
- QUIK 48.53
- Support Level
- ATOS $0.84
- QUIK $6.13
- Resistance Level
- ATOS $0.98
- QUIK $6.77
- Average True Range (ATR)
- ATOS 0.05
- QUIK 0.35
- MACD
- ATOS -0.01
- QUIK -0.04
- Stochastic Oscillator
- ATOS 7.65
- QUIK 26.57
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About QUIK QuickLogic Corporation
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.